Skip to main content
SpringerLink
Log in

Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (Δ2(E)-valproate) in healthy male volunteers

  • Published:
Pharmaceutisch Weekblad Aims and scope Submit manuscript

Abstract

2-n-Propyl-2(E)-pentenoic acid (Δ2(E)-valproate) was administered to healthy volunteers in oral doses of 50–800 mg. The drug was tolerated well and no significant adverse effects were observed. Pharmacokinetic parameters were determined. Valproate and 3-keto-valproate were detected as metabolites.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gram L, Bentsen KD. Valproate. An updated review. Acta Neurol Scand 1985;72:129–39.

    PubMed  Google Scholar 

  2. Schmidt D. Behandlung der Epilepsien. 2nd ed. Stuttgart: Georg Thieme Verlag, 1984:169–71.

    Google Scholar 

  3. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities. A retrospective review. Neurology 1987;37:379–85.

    PubMed  Google Scholar 

  4. Scheffner D, König S, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988;29:530–42.

    PubMed  Google Scholar 

  5. Gross-Selbeck G. Valproat — ein risikoreiches Medikament? Epilepsie-Blatt 1988;1(1).

  6. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid hepatic fatalities. II. US experience since 1984. Neurology 1989;39:201–7.

    PubMed  Google Scholar 

  7. Gomez MR. Possible teratogenicity of valproic acid. J Pediatr 1981;98:508–9.

    PubMed  Google Scholar 

  8. Jäger-Roman E, Deichel A, Jakob S, Hartmann A-M, Koch S, Rating D, et al. Fetal growth, major malformations and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986;108: 997–1004.

    PubMed  Google Scholar 

  9. DiLiberti JH, Farndon PA, Dennis NR, Curry CJR. The fetal valproate syndrome. Am J Med Gen 1984;19: 473–81.

    Article  PubMed  Google Scholar 

  10. Lammer EJ, Sever LE, Oakley GP. Teratogen update. Valproic acid. Teratology 1987;35:465–73.

    Article  PubMed  Google Scholar 

  11. Ardinger HH, Arkin JF, Blackstone RD, Elsas LJ, Clarren SK, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Gen 1988;29:171–85.

    Article  PubMed  Google Scholar 

  12. Nau H, Zierer R, Gansau C, Neubert D, Spielmann H. A new model for embryotoxicity testing: teratogenicity and pharmacokinetics of valproic acid following constant-rate administration in the mouse using human therapeutic drug and metabolite concentrations. Life Sci 1981;29:2803–14.

    Article  PubMed  Google Scholar 

  13. Kuhara T, Hirohata Y, Yamada S, Matsumoto I. Metabolism of sodium dipropylacetate in humans. Eur J Drug Metab Pharmacokinet 1978;3:171–7.

    Google Scholar 

  14. Taillandier G, Benot-Guyot J-L, Boucherle A, Broll M, Eymard P. Recherches dans la série dipropylacétique XII. Acides et alcools aliphatiques ramifiés anticonvulsivants. Eur J Med Chem Chim Ther 1975;10:453–62.

    Google Scholar 

  15. Löscher W.Trans-2-en-valproic acid. Drugs Future 1985;(10):389–91.

    Google Scholar 

  16. Löscher W, Nau H, Marescaux C, Vergnes M. Comparative evaluation of anticonvulsant and toxic potencies of valproic acid and 2-en-valproic acid in different animal models of epilepsy. Eur J Pharmacol 1984;99:211–8.

    Article  PubMed  Google Scholar 

  17. Löscher W, Böhme G, Schäfer H, Kochen W. Effect of metabolites of valproic acid on the metabolism of GABA in brain nerve endings. Neuropharmacology 1981;20:1187–92.

    Article  PubMed  Google Scholar 

  18. Keane PE, Simiand J, Morre M. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice. Meth Find Exp Clin Pharmacol 1985;7(2):83–6.

    Google Scholar 

  19. Anticonvulsant activity in rodents [internal report no: RS 300900 214/MC 2]. Montpellier: Sanofi, 1989.

  20. Nau H, Wittfoht W, Schäfer H, Jacobs C, Rating D, Helge H. Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constantrate application of the drug and its unsaturated metabolite with an osmotic delivery system. J Chromatogr 1981;226:69.

    PubMed  Google Scholar 

  21. Dreifuss FE, Langer DH. Side effects of valproate. Am J Med 1988;84 Suppl 1A:39–41.

    Article  PubMed  Google Scholar 

  22. Wilder BJ, Ramsay RE, Murphy JV, Karas BJ, Marquardt K, Hammond EJ. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology 1983;33:1474–6.

    PubMed  Google Scholar 

  23. Levy RH, Shen DD. Valproate. Absorption, distribution, and excretion. In: Levy R, Mattson R, Meldrum B, Penry JK, Dreifuss FE. Antiepileptic drugs. 3rd ed. New York: Raven Press, 1989.

    Google Scholar 

  24. Schulz HU, Lührmann B, Kraus G. Single dose bioavailability study of controlled release valproate: Orfiril® retard enteric coated tabletsvs Orfiril® enteric coated tablets [internal report, no: VPA-001]. Hamburg: Desitin Arzneimittel, 1990.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Desitin Arzneimittel, Postfach 63 01 20, D-2000, Hamburg 63, Germany

    R. H. Düsing

Authors
  1. R. H. Düsing
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Düsing, R.H. Single-dose tolerance and pharmacokinetics of 2-n-propyl-2(E)-pentenoate (Δ2(E)-valproate) in healthy male volunteers. Pharmaceutisch Weekblad Scientific Edition 14, 152–158 (1992). https://doi.org/10.1007/BF01962708

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01962708

Keywords

Search

Navigation